Wedbush Brokers Boost Earnings Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Analysts at Wedbush lifted their Q3 2025 earnings estimates for shares of Day One Biopharmaceuticals in a note issued to investors on Wednesday, April 24th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their previous forecast of ($0.33). Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ FY2025 earnings at ($1.40) EPS.

Several other equities research analysts have also recently weighed in on DAWN. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Needham & Company LLC increased their target price on shares of Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Finally, The Goldman Sachs Group reduced their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.33.

Day One Biopharmaceuticals Stock Up 3.6 %

Shares of Day One Biopharmaceuticals stock traded up $0.48 during trading on Friday, reaching $13.69. The company’s stock had a trading volume of 281,719 shares, compared to its average volume of 803,173. The business’s 50-day moving average price is $15.23 and its 200-day moving average price is $13.79. The firm has a market cap of $1.20 billion, a PE ratio of -5.71 and a beta of -1.48. Day One Biopharmaceuticals has a 52 week low of $9.67 and a 52 week high of $17.85.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $16.02, for a total transaction of $160,200.00. Following the completion of the transaction, the insider now owns 1,174,662 shares in the company, valued at approximately $18,818,085.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, General Counsel Adam Dubow sold 3,242 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total value of $49,440.50. Following the completion of the transaction, the general counsel now owns 16,585 shares of the company’s stock, valued at approximately $252,921.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Samuel C. Blackman sold 10,000 shares of the company’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the transaction, the insider now directly owns 1,174,662 shares of the company’s stock, valued at approximately $18,818,085.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,781 shares of company stock worth $883,160. 8.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC boosted its holdings in Day One Biopharmaceuticals by 58.7% in the third quarter. SG Americas Securities LLC now owns 36,980 shares of the company’s stock valued at $454,000 after purchasing an additional 13,683 shares during the period. Bank of New York Mellon Corp increased its position in Day One Biopharmaceuticals by 22.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock valued at $2,703,000 after acquiring an additional 40,387 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Day One Biopharmaceuticals by 24.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 43,567 shares of the company’s stock valued at $535,000 after acquiring an additional 8,522 shares during the period. TD Asset Management Inc increased its position in Day One Biopharmaceuticals by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 55,196 shares of the company’s stock valued at $677,000 after acquiring an additional 27,598 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its position in Day One Biopharmaceuticals by 89.5% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 53,803 shares of the company’s stock valued at $660,000 after acquiring an additional 25,414 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.